Health Care Higher as Regulatory Fears Recede -- Health Care Roundup

Features Dow Jones Newswires

Shares of health-care companies rose as fears about regulatory risks and pressures on drug prices subsided somewhat.

Continue Reading Below

Eli Lilly's lung-cancer treatment Alimta, which had $1.1 billion in U.S. sales last year, could have a generic competitor if a patent board accepts a challenge.

Rob Curran, rob.curran@dowjones.com

(END) Dow Jones Newswires

May 23, 2017 17:11 ET (21:11 GMT)